NDAORALTABLET
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Mechanism of Action
Dopamine Uptake Inhibitors
Pharmacologic Class:
Dopamine and Norepinephrine Reuptake Inhibitor
Clinical Trials (5)
Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
Started Feb 2025
300 enrolled
Binge-Eating Disorder
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Started Aug 2024
520 enrolled
Excessive SleepinessShift-work Disorder
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Started Jun 2024
46 enrolled
Multiple SclerosisMultiple Sclerosis Fatigue
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Started Apr 2024
450 enrolled
Binge-Eating Disorder
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Started Mar 2024
346 enrolled
Major Depressive Disorder
Loss of Exclusivity
LOE Date
Dec 30, 2042
204 months away
Patent Expiry
Dec 30, 2042
Exclusivity Expiry
Jun 17, 2026